Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program

Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program

                        Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program Submission Process Home
          Drugs
          Development & Approval Process | Drugs
          Drug Development Tool (DDT) Qualification Programs
          Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program
          Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program Submission ProcessInnovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program Submission Process
  
  	
    Share
    Post
    Linkedin

    Email
    PrintSubmission Process

The 21st Century Cures Act formally established a multi-step process for Drug Development Tools (DDT) qualification. Qualification of a DDT is for a specific context of use (COU), and the qualified DDT may be used for the COU by any person in drug or biologics development.

The qualification process includes three submissions:

the Letter of Intent (LOI),
	the Qualification Plan (QP),
	and the Full Qualification Package (FQP).Letter of Intent (LOI)

Applicants to the ISTAND Pilot Program begin by submitting a Letter of Intent to ISTAND@fda.hhs.gov. Content Elements for the LOI can be found on the LOI Content Elements file.

Following receipt of a completed LOI, ISTAND Pilot Program staff will review the letter and provide the applicant with information as to whether the submission has been admitted into the pilot and will progress to technical review. Admittance will be based on submission quality, drug development need, technology feasibility, and subject matter expert capacity. As this is a pilot program, capacity may be limited.

If an LOI is admitted for review, the applicant may be invited to present to the review staff. All such meeting proceedings will be confidential, and all discussions will be non-binding.

Next Steps

Following subject matter expert review, the DDT Committee makes the determination to accept or not accept a submission into the program based on several factors, including: the scientific merit of the submission, the ability of the DDT to address a specified drug development need, the availability of information and resources that support the proposed qualification effort, and demonstration that the DDT is feasible and practical. Although ISTAND’s goal is to qualify novel drug development tools for use in drug development programs, for some novel DDTs, qualification may not be the optimal path forward. In these cases, ISTAND will assist requestors and Agency subject matter experts to find the best path forward (e.g., guidance development or public meeting).

A determination to accept an LOI or a QP submission indicates that the requestor may proceed to the next stage, the QP or FQP, respectively, provided the requestor addresses the recommendations and comments in the Determination Letter. Applicants may not proceed from the LOI or QP stage to the next stage unless they are accepted at these stages.

                                                                                  Content current as of:
      11/30/2020
              
              
Regulated Product(s)
		 DrugsTopic(s)
			  Research
				    				       				    					
				  
				    
				  Drug Development ToolsLaw(s) & Regulation(s)
			  21st Century Cures Act of 2016Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program

          
                        Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program Submission Process
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop